Zobrazeno 1 - 10
of 5 802
pro vyhledávání: '"First line treatment"'
Autor:
Jing Zhang, Pei-Yuan Lv, Xiao Zhao, Ming-Lu Liu, Lu-Peng Qiu, Zi-Zhong Yang, Sheng-Jie Sun, Guo-Qing Zhang
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-9 (2024)
Abstract Background This study aimed to evaluate the effectiveness and safety of recombinant human endostatin (Rh-endostatin) plus programmed cell death 1 (PD-1) inhibitors and chemotherapy as first-line treatment for advanced or metastatic non-small
Externí odkaz:
https://doaj.org/article/5454b9a09a4d4af499f7dd40fb5f4407
Autor:
Urska Janzic, Natalie Maimon Rabinovich, Walid Shalata, Waleed Kian, Katarzyna Szymczak, Rafal Dziadziuszko, Marko Jakopovic, Giannis Mountzios, Adam Pluzanski, Antonio Araujo, Andriani Charpidou, Sameh Daher, Abed Agbarya
Publikováno v:
Current Oncology, Vol 31, Iss 8, Pp 4369-4381 (2024)
ROS1 rearrangements are considered rare in non-small-cell lung cancer (NSCLC). This retrospective real-world study aimed to evaluate first-line treatment with crizotinib, a tyrosine kinase inhibitor (TKI) standard of care vs. new generation ROS1 anti
Externí odkaz:
https://doaj.org/article/adb21f604fcc4328811acd70c304e952
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-13 (2024)
Abstract Programmed Death Receptor 1 (PD-1) inhibitors, when combined with chemotherapy, have exhibited notable effectiveness in enhancing the survival outcomes of patients afflicted with advanced gastric cancer. However, it is important to acknowled
Externí odkaz:
https://doaj.org/article/f05c8893e378418196ce28738cd77bf7
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
BackgroundThe efficacy and safety of enfortumab vedotin combined with pembrolizumab (EV-PEMB) was investigated as a first-line treatment for advanced urothelial carcinoma (UC) in a phase III clinical trial (EV-302). The trial findings indicated signi
Externí odkaz:
https://doaj.org/article/eb2396f2a8d64d1c9c85901495fb4620
Autor:
Petra Belohlavkova, Daniela Zackova, Hana Klamova, Edgar Faber, Michal Karas, Lukas Stejskal, Eduard Cmunt, Olga Cerna, Ivana Jeziskova, Katerina Machova Polakova, Pavel Zak, Tereza Jurkova, Marika Chrapava, Jiri Mayer
Publikováno v:
Cancer Medicine, Vol 13, Iss 17, Pp n/a-n/a (2024)
Abstract Background To evaluate the outcomes of first‐line imatinib versus nilotinib treatment for chronic myeloid leukemia in the chronic phase (CML‐CP) in real‐world clinical practice. Methods A propensity score analysis was performed to elim
Externí odkaz:
https://doaj.org/article/a3f1e095df1743329fc066dd5daac827
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
BackgroundAdvanced breast cancer (ABC) is a heterogeneous disease with varied prognoses, that is affected by many clinicopathological features. This study aimed to investigate the clinicopathological characteristics, first-line treatment (FLx), and p
Externí odkaz:
https://doaj.org/article/63d23351c40c468f86fd292e18e1850e
Autor:
Huiling Shi, Yong Tan, Chao Ma, Yushan Wei, Fengling Shi, Juan Wang, Caihua Xu, Rongrui Liang
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
ObjectiveTo evaluate the efficacy and safety of various first-line initial treatment systemic regimens for patients with unresectable esophageal squamous carcinoma(ESCC), utilizing a network meta-analysis approach.MethodsA comprehensive search for ra
Externí odkaz:
https://doaj.org/article/a617cf45871f41d4bb4b7bec68744912
Autor:
Brazel D, Nagasaka M
Publikováno v:
Lung Cancer: Targets and Therapy, Vol Volume 15, Pp 41-47 (2024)
Danielle Brazel,1 Misako Nagasaka2,3 1Department of Hematology/Oncology, Scripps Clinic/Scripps Green Hospital, La Jolla, CA, USA; 2Department of Hematology/Oncology, University of California Irvine School of Medicine, Chao Family Cancer Center, Oran
Externí odkaz:
https://doaj.org/article/f9fb353c5907470db3e3f0906bcee42c
Autor:
Mingqiang Shi, Zhoujuan Li, Guoshuang Shen, Tianzhuo Wang, Jinming Li, Miaozhou Wang, Zhen Liu, Fuxing Zhao, Dengfeng Ren, Jiuda Zhao
Publikováno v:
Cancer Pathogenesis and Therapy, Vol 2, Iss 2, Pp 81-90 (2024)
Background: Metastatic triple-negative breast cancer (mTNBC) is an aggressive histological subtype with poor prognosis. Several first-line treatments are currently available for mTNBC. This study conducted a network meta-analysis to compare these fir
Externí odkaz:
https://doaj.org/article/6439a61dbb12443393dd4799432f75d1
Autor:
Kleoniki Roka, Katrin Scheinemann, Shivaram Avula, John H. Maduro, Ulrich W. Thomale, Astrid Sehested, A.Y.N. Schouten-Van Meeteren
Publikováno v:
EJC Paediatric Oncology, Vol 4, Iss , Pp 100169- (2024)
Pediatric low-grade gliomas are the most common brain tumours in childhood and adolescence. Despite the excellent prognosis, pediatric low-grade glioma survivors may suffer from variable long-term complications and may require repeated therapies, imp
Externí odkaz:
https://doaj.org/article/ae2892d7413847afb3e9757bac718a35